RecruitingDementia Alzheimer TypeDementia Associated With Cerebrovascular Disease
Rifaximin SSD in Dementia Trial
Eligible age
65+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Using a new formulation of rifaximin, a non-absorbable antibiotic, to test if it can affect microbes in the gut of patients with dementia favorably.
Sponsor: Jasmohan Bajaj
You may qualify if…
- ✓ Probable Alzheimer's Disease (AD) or Vascular Dementia (VaD) mild or moderate based on Clinical Dementia Rating Scale.
- ✓ Males and Females Age ≥ 65 years
- ✓ Community living with availability of caregiver to accompany participant to study visits and to participate in the study.
- ✓ Able to consent or legal guardian who can consent (with participant assent).
- ✓ Legally authorized representative (LAR) and caregiver for the study is the same individual.
- ✓ Fluency (both participant and caregiver) in written and spoken English to participate in study visits.
You may not qualify if…
- ✕ Dementia not due to AD or VaD
- ✕ Clinically significant agitation or aggression (requiring treatment with antipsychotic medication)
- ✕ Delusions and/or hallucinations
- ✕ Severe psychopathology including major depression
- ✕ Unstable, severe, or poorly controlled medical conditions evident from physical examination or clinical history
- ✕ Visual and/or hearing disorder that prevents completion of neuropsychologic evaluations.
- ✕ Diarrhea
- ✕ Hypersensitivity to rifaximin, components of rifaximin,
Where it's recruiting
Virginia
Richmond
Source: ClinicalTrials.gov · NCT06718686 · last updated 2026-04-03